Price$10.78-0.35 (-3.14%)
01:30 PM03:15 PM
News · 26 weeks37+100%
2025-12-072026-05-31
Mix1890d
- Other6(33%)
- SEC Filings5(28%)
- Insider5(28%)
- Earnings2(11%)
Latest news
25 items- FDAFDA Approval for HEPZATO issued to DELCATH SYSTEMS INCSubmission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-16) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/29/2026. Application Category: NDA, Application Number: 201848, Application Classification: REMS
- PRDelcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress AbstractsDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The abstracts highlight ongoing clinical investigations evaluating the use of Delcath's percutaneous hepatic perfusion (PHP) with melphalan using the HEPZATO KIT™ Hepatic Delivery System (HDS) in metastatic melanoma involving the liver — a common and difficult-to-treat site of disease progression. One abstract, titled "Phase
- PRDelcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either March 2026 or April 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 24,500 shares of the Company's common stock and are subject to the terms and conditions of the Company's 2023 Inducement Plan ("Plan"). The RSUs were granted on May 1, 2026 and one-third of the RSUs will vest on the first anniversary of th
- INSIDERSEC Form 4 filed by Director Sylvester John Richard4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
- INSIDERSEC Form 4 filed by Director Martell Bridget A4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
- INSIDERSEC Form 4 filed by Director Aharon Gil4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
- INSIDERSEC Form 4 filed by Director Salamon Steven A J4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
- INSIDERSEC Form 4 filed by Director Czerepak Elizabeth4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
- SECSEC Form 8-K filed by Delcath Systems Inc.8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)
- PRDelcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor ConferenceDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New York, NY. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are desig
- SECSEC Form 10-Q filed by Delcath Systems Inc.10-Q - DELCATH SYSTEMS, INC. (0000872912) (Filer)
- SECDelcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)
- PRDelcath Systems Reports First Quarter 2026 Results and Business Highlights2026 Revenue Guidance of at least $100M Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2026. First Quarter 2026 Financial Results Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025 HEPZATO KIT™ revenue of $23.3 million, compared to $18.0 million in the first quarter of 2025 CHEMOSAT® revenue of $1.7 million, compared to $1.8 million in the first quarter of 2025 Gross margins of 85%, compared to 86% in t
- PRDelcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective analysis by independent investigators on percutaneous hepatic perfusion with melphalan (M-PHP) using the CHEMOSAT® Hepatic Delivery System was presented today at the ESMO Breast Cancer Congress 2026. Presentation details Congress: ESMO Breast Cancer Congress 2026 Date: May 7, 2026 Session: 13:15 (local congress time) Format: E-poster Title: Safety and Feasibility of Percutaneous Hepatic Perfusion with Melphalan in Patients with Liver-Dominant Metastatic Breast Cancer Presenter:
- PRDelcath Systems to Host First Quarter 2026 Earnings CallDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 7, 2026 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-800-717-1738 International: 1-646-307-1865 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1757946&tp_key=463dd4d428 A replay of the webinar will be available short
- PRDelcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal MelanomaDelcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included as a recommended liver-directed regional therapy option in the newly published Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up (April 2026). M-PHP is also recognized in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Metastatic Uveal Melanoma. HEPZATO KIT™ (also referred to as melphalan/HDS), is included as a Category 2A recommended treatment
- SECSEC Form DEFA14A filed by Delcath Systems Inc.DEFA14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)
- SECSEC Form DEF 14A filed by Delcath Systems Inc.DEF 14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)
- INSIDERChief Financial Officer Pennell Sandra bought $50,018 worth of shares (5,533 units at $9.04), increasing direct ownership by 8% to 77,018 units (SEC Form 4)4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
- SECSEC Form 8-K filed by Delcath Systems Inc.8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)
- INSIDERCHIEF EXECUTIVE OFFICER Michel Gerard J bought $100,309 worth of shares (11,200 units at $8.96), increasing direct ownership by 3% to 342,034 units (SEC Form 4)4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)
- PRDelcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet OncologyPublication Highlights Promise of Combined Percutaneous Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology. The publication, titled "Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre
- SECSEC Form 10-K filed by Delcath Systems Inc.10-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)
- SECDelcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)
- PRDelcath Systems Reports Fourth Quarter and Full Year 2025 ResultsConference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively Gro
DCTH FAQ
6 questionsWhat does Delcath Systems Inc. do?
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the...Where does DCTH stock trade?
Delcath Systems Inc. (DCTH) is listed on NASDAQ.What sector and industry is DCTH in?
Delcath Systems Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about DCTH?
Delcath Systems Inc. has had 4 recent analyst actions on file. The most recent action was from Craig Hallum: Buy with a $1800.00 price target on 2024-06-28. Recent price targets range from $1700.00 to $2500.00.What companies are similar to DCTH?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare DCTH side-by-side with any of them on Quantisnow.How can I track DCTH on Quantisnow?
Quantisnow aggregates Delcath Systems Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DCTH to receive live email and push alerts on every new disclosure.